NEWS

AstraZeneca Says Acalabrutinib Recommended for Orphan Drug Designation in Europe

Friday, Feb 26, 2016

Astrazeneca Plc Acalabrutinib orphan drug designation recommended.

Acalabrutinib recommended for orphan drug designation in europe for three indications.

3 positive opinions are for treatment of cll/sll, mantle cell lymphoma mcl and lymphoplasmacytic lymphoma.

 

Source : reuters.com